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By January 2005, clonal chromosomal aberrations identifi d by various banding techniques had been report d in 
more than 47,000 human neoplasms (Mitelman et al., 2005a). An increasing number of the acquired 
abnormalities have now also been studied by various fluorescence in situ hybridization techniques, which have 
provided a new and powerful tool to identify abnormal chromosomes and to visualize very small rearrangements 
that escape detection by conventional chromosome banding. The new techniques have also added a further 
sophistication to the analyses in that breakpoints in structural aberrations can be delineated within specific genes. 
Furthermore, an ever increasing number of breakpoints f the cancer-associated chromosome abnormalities have 
been characterized at the molecular level, and the combined efforts of cytogeneticists and molecular geneticists 
over the past two decades have led to the identification of 275 genes rearranged as a consequence of 
chromosome aberrations in neoplasia (Mitelman et al., 2004).
Specific chromosomal rearrangements 
The main conclusion from modern cancer cytogenetics 
is the realization that every tumor type that has been 
studied in a sufficient number to permit conclusion 
may be subdivided on the basis of characteristic 
chromosome abnormalities (Mitelman et al., 2005b). 
Many of these, in particular balanced rearrangements, 
most commonly translocations, are with remarkable 
specificity associated with distinct tumor subtypes. At 
present, almost 500 recurrent balanced neoplasia-
associated aberrations have been identified. However, 
in spite of the very rapid, almost exponential, increase 
of information over the past decade, the available data 
are, due to technical difficulties, still heavily biased in 
favor of the hematological malignancies. Solid tumors 
constitute less than one-third of all cases with an 
abnormal karyotype reported in the literature. This is of 
course totally disproportionate in relation to their 
relative contribution to human cancer morbidity and 
mortality. For example, the malignant epithelial 
tumors, which cause 80% of human cancer deaths, 
constitute only 10% of the database. Thus, for most 
individual solid tumor types our knowledge is still only 
fragmentary.  
In addition to the limited information on the 
cytogenetics of solid tumors, there are a number of 
analytical problems that diminish the value of the 
existing data. First, the chromosome quality in solid 
tumors, in particular epithelial neoplasms, is often 
suboptimal, and hence many of the published cases 
have actually only been partially karyotyped. Second, 
in contrast to the hematological disorders, which often 
contain few cytogenetic changes, most solid tumors 
have already at the time of diagnosis a multitude of 
aberrations acquired during tumor progression. This 
karyotypic complexity may be truly massive, rendering 
the identification of the various abnormalities 
practically impossible. So, even when the quality is 
good and each abnormality can be characterized, the 
distinction between primary, pathogenetically essential, 
changes and secondary evolutionary aberrations is a a 
rule more difficult in solid tumors than in 
hematological malignancies. Consequently, a large 
number of cytogenetically well-analyzed tumors of 
each entity is required in order to identify the relevant 
early abnormalities. Finally, clonal heterogeneity in the 
form of cytogenetically unrelated clones introduces a 
further dimension of complexity in the analysis of s lid 
tumors, in particular as regards epithelial tumors. This 
phenomenon, seen in less than 5% of leukemias, 
lymphomas, and mesenchymal tumors, has been 
reported in up to 80% of various carcinomas. The 
aberrations are usually simple and balanced, the clones 
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are often small, but they may be numerous (Gorunova 
et al., 1998) and hence pose important analytical 
problems.  
Obviously, more cytogenetic information is urgently 
needed, especially for many solid tumor types, in order 
to establish whether or not there are any principal 
tissue-specific differences in the mechanisms of 
aberration formation. The fact that tumors of various 
histologic derivations are characterized by, in principle, 
similar kinds of recurrent balanced abnormalities and 
that the fractions of recurrent balanced rearrangements 
are similar within different tumor classes (Mitelman et 
al., 2004) suggest that there may be no fundamental 
differences. There is one apparent quantitative 
difference in that the balanced, simple, and disease-
specific changes are found in about one third of the 
acute leukemias and malignant lymphomas, 20% of the 
mesenchymal tumors, but in less than 5% of the 
epithelial tumors. What is the explanation for this 
uneven distribution? Does it reflect a true biologic 
difference or could it be that as yet unidentified 
primary balanced rearrangements are hidden in 
complex karyotypes and unrelated clones? Such 
aberrations may be individually very rare (Mitelman et 
al., 2005b). It has been proposed that balanced and 
unbalanced abnormalities most likely are functionally 
distinct – primary, pathogenetically essential, changes 
are cytogenetically balanced whereas the secondary, 
progression-related, aberrations are unbalanced 
(Johansson et al., 1996). This suggestion remains 
hypothetical, but it has a number of conceptual 
ramifications, in this context in particular that primary 
balanced rearrangements may be present when only 
unbalanced changes are detected.  
Molecular consequences of 
chromosome rearrangements 
All balanced structural abnormalities that have been 
characterized at the molecular level have been found to 
exert their action through one of two alternative 
mechanisms: deregulation, usually overexpression, of a 
gene in one breakpoint, or creation of a hybrid gene 
through fusion of parts of two genes, one in each 
breakpoint (Mitelman et al., 1997; Rowley, 2001; 
Helman & Meltzer, 2003). The first mechanism, 
common in lymphoid malignancies but seemingly quite 
rare in other tumor types, juxtaposes regulatory 
alements of a constitutively active gene, typically 
immunoglobulin and T-cell receptor genes, to the 
coding sequences of a normally silent target gene. 
More than 70 such gene rearrangements have now been 
documented (Mitelman et al., 2005a). The second 
mechanism, fusion of parts of various differentiation- 
and proliferation-regulating genes, often transcription 
control genes and genes encoding tyrosine kinases, has 
been described in hematological disorders, malignant 
lymphomas, and solid tumors. More than 200 different 
fusion genes are presently known (Mitelman et al., 
2005a). It is of interest in this context that some genes 
are highly promiscuous in that they may recombine 
with many different partners, usually within the same 
tumor entities, e.g., MLL in acute leukemias (Collins & 
Rabbitts, 2002), EWSR1 in bone- and soft tissue 
tumors (Helman & Meltzer, 2003), and RET in thyroid 
carcinomas (Pierotti, 2001). However, the same fusion 
gene may also give rise to tumors of totally different 
derivations, and one particular fusion gene, ETV6-
NTRK3, has been described in entities as diverse as 
acute myeloid leukemia, infantile fibrosarcoma, 
mesoblastic nephroma, and breast carcinoma (Tognon 
et al., 2002). There are now also several examples 
where seemingly identical aberrations produce different 
fusion genes. One of the most common translocations 
in pre-B acute lymphoblastic leukemia, 
t(1;19)(q23;p13) leading to a TCF3/PBX1 fusion, may 
result in a chimeric transcript consisting of two entirely 
different genes, MEF2D in 1q23 and DAZAP1 in 
19q13 (Yuki et al., 2004). Finally, several cryptic 
disease-specific rearrangements leading to fusion genes 
in cases with either normal karyotypes or with 
unbalanced changes have been reported (Romana et al., 
1995; Pierotti, 2001). It thus seems reasonable to 
assume that the presently known gene rearrangements 
only represent the tip of an iceberg.  
Conclusions 
It now seems convincingly clear that the neoplastic 
phenotype is caused by a stepwise accumulation of 
genetic and epigenetic alterations (Hanahan & 
Weinberg, 2000; Vogelstein & Kinzler, 2004). The role 
played by genomic instability to initiate and promote 
the genetic variation is still controversial (Lengauer et 
al., 1998), but there is little doubt that the quantit tive 
or qualitative gene changes caused by balanced 
cytogenetic abnormalities represent an important step 
in the initiation of the carcinogenic process. The 
identification of every recurrent cytogenetic change is 
therefore of great importance because the breakpoints 
point to the location of directly cancer-relevant genes. 
The alternative initiating mechanism - inactivation, 
often through mutations and deletions, of tumor 
suppressor genes - has been well documented in several 
familial cancer forms, in particular childhood tumors, 
e.g., retinoblastoma and Wilm's tumor (Knudson, 2001; 
Vogelstein & Kinzler, 2004), and similar mechanisms 
have also been implicated in, e.g., lung, breast, and
kidney carcinoma. In these and several other common 
cancers of adult life, loss of tumor suppressor genes 
may be suspected because chromosomal regions are 
found to be consistently lost in the tumor cells (Mertens 
et al., 1997), but it is unclear what role, if any, such 
genes play in the initiation process of most sporadic 
cancers. Since most recurrent balanced cytogenetic 
abnormalities and genes rearranged as a consequence 
of such aberrations have been found in hematologic 
disorders and bone and soft tissue tumors, whereas 
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numerous genomic imbalances, but seemingly few 
balanced abnormalities, have been identified in 
epithelial tumors (Albertson et al., 2003; Futreal t al., 
2004), it has become generally accepted that 
deregulation or fusion of genes as a consequence of 
balanced cytogenetic aberrations is the preferred 
initiating event in hematological disorders and 
mesenchymal tumors, whereas functional abrogation of 
tumor suppressor genes is of essence in epithelial 
carcinogenesis. It was, however, shown recently 
(Mitelman et al., 2004) that the ratios of the numbers of 
gene fusions and genes rearranged as a consequence of 
balanced rearrangements to the numbers of 
cytogenetically investigated cases are similar among 
tumor entities, irrespective of their histogenetic 
derivation. The obvious conclusion is hence that there 
may not be any fundamental tissue-specific differences 
in the genetic mechanisms by which neoplasia is 
initiated.  
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